[1]官泳松,贺庆.肝癌介入治疗中应用p53的几个要点[J].介入放射学杂志,2008,(11):761.
 GUAN Yongsong,HE Qing.Essentials in clinical application of p53for tumors intervention-example of liver cancer[J].journal interventional radiology,2008,(11):761.
点击复制

肝癌介入治疗中应用p53的几个要点()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2008年11期
页码:
761
栏目:
述评
出版日期:
2008-11-15

文章信息/Info

Title:
Essentials in clinical application of p53for tumors intervention-example of liver cancer
作者:
官泳松贺庆
610041四川大学华西医院四川大学生物治疗国家重点实验室
Author(s):
GUAN Yong-songHE Qing.
State Key Laboratory of Biotherapy,West China Hospital,West China Medical School,Sichuan University,Chengdu610041,China
关键词:
重组人p53腺病毒注射液经导管动脉化疗栓塞肝癌协同作用
分类号:
R735.7
文献标志码:
C
摘要:
重组人p53腺病毒注射液(recombinant human adenovirus p53,Ad-p53)已被用于与多种局部治疗方法联合治疗肿瘤。本文介绍在肝癌介入治疗过程中联合应用Ad-p53,应该重点研究两者的机制,最大限度地发挥它们抗肿瘤的协同作用。提出瘤内注射是首选的基因给药途径,建议单个肿瘤注射Ad-p53的最低用量,以及注射Ad-p53后进行肝癌介入治疗的最佳时机。介绍以p53为靶点的治疗方法有好几种理论基础,有些方法甚至相互对立,因此在治疗前须先明确要对p53进行激活还是抑制。最后提出应用Ad-p53治疗晚期恶性肿瘤应慎重选择病例。

参考文献/References:

[1]Cross D,Burmester JK.Gene therapy for cancer treatment :past,present and future[J].Clin Med Res,2006,4:218-227.
[2]Roth JA.Adenovirus p53gene therapy[J].Expert Opin Biol Ther,2006,6:55-61.
[3]Zhang S,Xu G,Liu C,et al.Clinical study of recombinant adenovirus p53(Adp53)combined with hyperthermia in advanced cancer(a report of15cases)[J].Int J Hyperthermia,2005,21:631-636.
[4]Van Dyke T.p53and tumor suppression[J].N Engl J Med,2007,356:79-81.
[5]Levesque AA,Eastman A.p53based cancer therapies:Is defective p53the Achilles heel of the tumor[J]?Carcinogenesis,2007,28:13-20.
[6]Shen Y,Liu P,Zhang A,et al.Tumor microvasculature response to alternated cold and heat treatment [J].Conf Proc IEEE Eng Med Biol Soc,2005,7:6797-6800.
[7]Cepeda V,Fuertes MA,Castilla J,et al.Biochemical mechani-sms of cisplatin cytotoxicity[J].Anticancer Agents Med Chem,2007,7:3-18.
[8]Eisold S,Linnebacher M,Ryschich E,et al.The effect of adeno-virus expressing wild type p53on5fluorouracil chemose-nsitivity is related to p53status in pancreatic cancer cell lines[J].World J Gastroenterol,2004,10:3583-3589.
[9]Fabregat I,Roncero C,Fernandez M.Survival and apoptosis:a dysregulated balance in liver cancer[J].Liver Int ,2007,27:155-162.
[10]Atencio IA,Grace M,Bordens R,et al.Biological activities of a recombinant adenovirus p53(SCH58500)administered by hepatic arterial infusion in a Phase1colorectal cancer trial[J].Cancer Gene Ther,2006,13:169-181.
[11]Pichla-Gollon SL,Drinker M,Zhou X,et al.Structure based identification of a major neutralizing site in an adenovirus hexon[J].J Virol,2007,81:1680-1689.
[12]Lutz W,Nowakowska-Swirta E.Gene p53mutations,protein p53,and anti-p53antibodies as biomarkers of cancer process[J].Int J Occup Med Environ Health,2002,15:209-218.
[13]Yu ZW,Zhao P,Liu M,et al.Reversal of5flouroucial resis-tance by adenovirus mediated transfer of wild type p53gene in multidrug resistant human colon carcinoma LoVo /5FU cells[J].World J Gastroenterol,2004,10:1979-1983.
[14]Balint EE,Vousden KH.Activation and activities of the p53tumour suppressor protein[J].Br J Cancer,2001,85:1813-1823.
[15]Vigano A,Dorgan M,Bruera E,et al.The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer[J].Cancer,1999,86:170-176.
[16]Vigano A,Bruera E,Jhangri GS,et al.Clinical survival pre-dictors in patients with advanced cancer[J].Arch Intern Med,2000,160:861-868.
[17]Fried TR,Bradley EH,Towle VR,et al.Understanding the treatment preferences of seriously ill patients[J].N Engl J Med,2002,346:1061-1066.

相似文献/References:

[1]沈海洋,杨光,刘瑞宝,等.肝右叶前、后段原发性肝癌动脉化疗栓塞术后近期疗效比较[J].介入放射学杂志,2010,(05):382.
 SHEN Haiyang,YANG Guang,LIU Ruibao,et al.Short-term effects of TACE for primary hepatocellular carcinoma of the right hepatic lobe:a comparison between the lesions in anterior segments and the lesions in posterior segments[J].journal interventional radiology,2010,(11):382.
[2]张训,徐燕能,张向琼,等.CalliSpheres载药微球联合碘化油治疗大肝癌14例[J].介入放射学杂志,2020,29(01):39.
 ZHANG Xun,XU Yanneng,ZHANG Xiangqiong,et al.CalliSpheres drug-eluting beads combined with lipiodol for TACE treatment of large liver cancer in 14 patients[J].journal interventional radiology,2020,29(11):39.

备注/Memo

备注/Memo:
收稿日期:2008-04-02
更新日期/Last Update: 2008-11-15